Successful Management of Checkpoint Inhibitor-Induced Arthritis With Disease-Modifying Antirheumatic Drugs During Active Immune Checkpoint Inhibition Treatment
The Journal of Rheumatology · 2023
DOI: 10.3899/jrheum.221182 ↗Kurz gefasst
Leserbrief in der Zeitschrift The Journal of Rheumatology, 2023. Verfasst von Helga B Brynjarsdottir und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg; helga.bjork.brynjarsdot…. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Arthritis induced by immune checkpoint inhibitors (ICPi) has been reported to occur in 1% to 7% of ICPi-treated patients with cancer.1-4 Treatment generally starts with glucocorticoids (GCs) before disease-modifying antirheumatic drugs (DMARDs) are considered.5
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg; helga.bjork.brynjarsdottir@gu.se.
- Department of Rheumatology, Sahlgrenska University Hospital.
- Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg.
- Department of Oncology, Sahlgrenska University Hospital.
- Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
- Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg.
ORCID-Profile: Helga B Brynjarsdottir
Zitieren
APA
Brynjarsdottir, H. B., Bjursten, S., Levin, M., Gjertsson, I., & Rudin, A. (2023). Successful Management of Checkpoint Inhibitor-Induced Arthritis With Disease-Modifying Antirheumatic Drugs During Active Immune Checkpoint Inhibition Treatment. The Journal of Rheumatology. https://doi.org/10.3899/jrheum.221182
Vancouver
Brynjarsdottir HB, Bjursten S, Levin M, Gjertsson I, Rudin A. Successful Management of Checkpoint Inhibitor-Induced Arthritis With Disease-Modifying Antirheumatic Drugs During Active Immune Checkpoint Inhibition Treatment. The Journal of Rheumatology. 2023. doi:10.3899/jrheum.221182
BibTeX
@article{Brynjarsdottir2023,
author = {Brynjarsdottir, Helga B and Bjursten, Sara and Levin, Max and Gjertsson, Inger and Rudin, Anna},
title = {Successful Management of Checkpoint Inhibitor-Induced Arthritis With Disease-Modifying Antirheumatic Drugs During Active Immune Checkpoint Inhibition Treatment},
journal = {The Journal of Rheumatology},
year = {2023},
doi = {10.3899/jrheum.221182}
}
EUVIMED